Litcius/Paper detail

Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study

Georgina V. Long, Victoria Atkinson, Serigne Lo, Alexander Guminski, Shahneen Sandhu, Michael P. Brown, Maria Gonzalez, Grant A. McArthur, Alexander M Menzies

2025The Lancet Oncology39 citationsDOI

Topics & Concepts

NivolumabIpilimumabMedicineOpen labelMelanomaOncologyOpen label studyMetastatic melanomaMaximum tolerated doseInternal medicineClinical trialAdverse effectCancerImmunotherapyCancer researchBrain Metastases and TreatmentCancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management
Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study | Litcius